Power in Numbers: Harnessing Combinatorial and Integrated Screens to Advance Nanomedicine
Name
boehnke-hammond-2021-power-in-numbers-harnessing-combinatorial-and-integrated-screens-to-advance-nanomedicine.pdf
Description
Published version
Size
2.35 MB
Format
Adobe PDF
Checksum (MD5)
0a45f7128067bd89d3bcdec0f755fd56
Author(s)
Boehnke, Natalie
Hammond, Paula T
Date Issued
November 23, 2021
Journal
JACS Au
Publisher
American Chemical Society
Citation
Natalie Boehnke and Paula T. Hammond. JACS Au 2022 2 (1), 12-21.
Version
Final published version
Abstract
Nanocarriers have significant potential to advance personalized medicine through targeted drug delivery. However, to date, efforts to improve nanoparticle accumulation at target disease sites have largely failed to translate clinically, stemming from an incomplete understanding of nano-bio interactions. While progress has been made to evaluate the effects of specific physical and chemical nanoparticle properties on trafficking and uptake, there is much to be gained from controlling these properties singularly and in combination to determine their interactions with different cell types. We and others have recently begun leveraging library-based nanoparticle screens to study structure-function relationships of lipid- and polymer-based drug delivery systems to guide nanoparticle design. These combinatorial screening efforts are showing promise in leading to the successful identification of critical characteristics that yield improved and specific accumulation at target sites. However, there is a crucial need to equally consider the influence of biological complexity on nanoparticle delivery, particularly in the context of clinical translation. For example, tissue and cellular heterogeneity presents an additional dimension to nanoparticle trafficking, uptake, and accumulation; applying imaging and screening tools as well as bioinformatics may further expand our understanding of how nanoparticles engage with cells and tissues. Given recent advances in the fields of omics and machine learning, there is substantial promise to revolutionize nanocarrier development through the use of integrated screens, harnessing the combinatorial parameter space afforded both by nanoparticle libraries and clinically annotated biological data sets in combination with high throughput in vivo studies.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Massachusetts Institute of Technology. Department of Chemical Engineering
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivatives
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1021/jacsau.1c00313
